Spatiotemporal prime-boost nanovaccine for potent therapeutic and prophylactic anti-melanoma immunity
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Cancer vaccines10.1200/JCO.1999.17.3.1047 ↗
2. Cancer vaccines: current status and future directions10.1186/s13045-025-01670-w ↗
3. Cancer immunotherapy via dendritic cells10.1038/nrc3258 ↗
4. Glucosylated nanovaccines for dendritic cell-targeted antigen delivery and amplified cancer immunotherapy10.1021/acsnano.4c09053 ↗
5. Regulatory considerations for clinical development of cancer vaccines10.4161/21645515.2014.982999 ↗
6. Cancer vaccines and the future of immunotherapy10.1016/S0140-6736(25)00553-7 ↗
7. Therapeutic cancer vaccines: advancements, challenges, and prospects10.1038/s41392-023-01674-3 ↗
8. Cancer vaccines: platforms and current progress10.1186/s43556-024-00241-8 ↗
9. Proton-driven transformable nanovaccine for cancer immunotherapy10.1038/s41565-020-00782-3 ↗
10. Designer vaccine nanodiscs for personalized cancer immunotherapy10.1038/nmat4822 ↗
11. Dendritic cell biology and its role in tumor immunotherapy10.1186/s13045-020-00939-6 ↗
12. Control of dendritic cell function within the tumour microenvironment10.3389/fimmu.2022.733800 ↗
13. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?10.1158/0008-5472.CAN-04-2048 ↗
14. Materials engineering strategies for cancer vaccine adjuvant development10.1039/D2CS00647B ↗
15. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway10.1038/ncomms2874 ↗
16. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial10.1158/1078-0432.CCR-09-1544 ↗
17. Duration, combination and timing: the signal integration model of dendritic cell activation10.1016/j.it.2007.03.008 ↗
18. IRAK-M is a negative regulator of Toll-like receptor signaling10.1016/S0092-8674(02)00827-9 ↗
19. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses10.1038/ni1110 ↗
20. A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion10.1038/s41565-022-01296-w ↗
21. Spatiotemporal nano-regulator unleashes anti-tumor immunity by overcoming dendritic cell tolerance and T cell exhaustion in tumor-draining lymph nodes
22. Linked toll-like receptor triagonists stimulate distinct, combination-dependent innate immune responses10.1021/acscentsci.8b00823 ↗
23. Rigid nanoparticles for efficient tumor immunotherapy through mechanical force mediated reprogramming of tumor-associated macrophages10.1016/j.cej.2024.152129 ↗
24. Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment10.1038/s41467-025-60448-3 ↗
25. situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy
26. Dictating the spatial-temporal delivery of molecular adjuvant and antigen for the enhanced vaccination10.1016/j.biomaterials.2024.122697 ↗
27. Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity10.1038/s41586-019-1485-8 ↗
28. Mechanically activated ion channel Piezo1 modulates macrophage polarization and stiffness sensing10.1038/s41467-021-23482-5 ↗
29. Tuning immunity through tissue mechanotransduction10.1038/s41577-022-00761-w ↗
30. Regulation of type I interferon responses10.1038/nri3581 ↗
31. Mechanoimmune-driven backpack sustains dendritic cell maturation for synergistic tumor radiotherapy10.1021/acsnano.4c08701 ↗
32. Metal-doping engineering-driven STING-PANoptosis cascade for enhanced cancer sono-immunotherapy
33. Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer
34. NF-KB activation enhances STING signaling by altering microtubule-mediated STING trafficking
35. Lanthanide-nucleotide coordination nanoparticles for STING activation10.1021/jacs.2c03266 ↗
36. Click-chemistry-mediated cell membrane glycopolymer engineering to potentiate dendritic cell vaccines
37. Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity10.1038/s41467-024-50474-y ↗
38. Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity10.1016/j.biomaterials.2023.122062 ↗
39. Bacterial biohybrids for invasion of tumor cells promote antigen cross-presentation through gap junction
40. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma10.1021/acsnano.5b01042 ↗
41. Direct presentation of tumor-associated antigens to induce adaptive immunity by personalized dendritic cell-mimicking nanovaccines10.1002/adma.202205950 ↗
42. Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality10.1016/j.biomaterials.2018.02.033 ↗
43. Spleen-targeted mRNA vaccine doped with manganese adjuvant for robust anticancer immunity in vivo10.1021/acsnano.4c09902 ↗